Company Profile

Axys Pharmaceuticals Inc (AKA: Sequana Therapeutics Inc~Akkadix Corporation)
Profile last edited on: 3/15/19      CAGE:       UEI:

Business Identifier: Small-molecule drug discovery
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

180 Kimball Way
South San Francisco, CA 94080
   (858) 452-6550
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Formerly doing business as Arris Pharmceuticals and as Akkadix Corporation. Axys Pharmaecuticals was formed when Arris joined with Sequana Therapeutics in January 98. Functioning as a edicinal and structural chemistry company Axys was then itself acquired by Applera's Celera Genomics. The original firm was a genomics company focused on discovery, design, and development of therapeutic small molecules that used industrial-scale gene finding technologies, advanced biology and bioinformatics to uncover the genetic cause of common human diseases. With gene discovery programs in asthma, diabetes, obesity, osteoporosis, schizophrenia, manic depression, prostate cancer and other important disease areas, Sequana is well-positioned to find disease-causing genes, determine their biological function, and translate gene discoveries into novel diagnostic and therapeutic products.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 2 NIH $926,426
Project Title: Prediction of Protein Function at the Industrial Scale
2000 2 NIH $926,426
Project Title: Prediction Of Protein Function At The Industrial Scale
1997 1 NIH $99,743
Project Title: Large Scale Gene Targeting For Functional Genomics

Key People / Management

  Kevin J Kinsella -- President

  Douglas H Altschuler -- Vice President

  Jeffrey Horn

  Acady R Mushegian

  Acady R Mushegian

  Michael C Venuti -- Vice President For Research And Developmen

Company News

There are no news available.